• +1-646-491-9876
    • +91-20-67278686

    Search

    Botulism - Pipeline Review, H1 2017

    Botulism - Pipeline Review, H1 2017

    • Report Code ID: RW0001689426
    • Category Healthcare
    • No. of Pages 47
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Botulism - Pipeline Review, H1 2017, provides an overview of the Botulism (Infectious Disease) pipeline landscape.

    Botulism is a rare but serious illness. The cause is a toxin (poison) made by a bacterium called Clostridium botulinum. It occurs naturally in soil. Food borne botulism comes from eating foods contaminated with the toxin. Symptoms include double or blurred vision, drooping eyelids, slurred speech, difficulty swallowing, dry mouth, and muscle weakness. Treatment may include antitoxins, intensive medical care, or surgery of infected wounds.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Botulism - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Botulism (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Botulism (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Botulism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 7 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

    Botulism (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Botulism (Infectious Disease).
    - The pipeline guide reviews pipeline therapeutics for Botulism (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Botulism (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Botulism (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Botulism (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Botulism (Infectious Disease).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Botulism (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Botulism - Overview
    Botulism - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Botulism - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Botulism - Companies Involved in Therapeutics Development
    CytoDel LLC
    Hawaii Biotech Inc
    Medy-Tox Inc
    Microbiotix Inc
    Nanotherapeutics Inc
    Planet Biotechnology Inc
    XOMA Corp
    Botulism - Drug Profiles
    BoNT/A HcR4 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    botulism [serotype C] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    botulism [serotypes A, B, C, D, E] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    botulism [serotypes A, B, E] (trivalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Ctyo-111 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit Botulinum Neurotoxin Type A for Botulism - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit Botulinum Toxin for Botulism - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NTM-1634 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OSX-400 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OSX-400 Backups - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Polyclonal Antibody to Inhibit Botulinum Toxin for Botulism - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Peptides to Inhibit Botulinum Toxin for Botulism - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Botulism - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit BoNT/A LC for Botulism - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Botulinum Neurotoxin Type A for Botulism - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    XOMA-3-BB - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    XOMA-3AB - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Botulism - Dormant Projects
    Botulism - Discontinued Products
    Botulism - Product Development Milestones
    Featured News & Press Releases
    May 03, 2011: XOMA 3AB, New Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase I Clinical Testing
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Botulism, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Botulism - Pipeline by CytoDel LLC, H1 2017
    Botulism - Pipeline by Hawaii Biotech Inc, H1 2017
    Botulism - Pipeline by Medy-Tox Inc, H1 2017
    Botulism - Pipeline by Microbiotix Inc, H1 2017
    Botulism - Pipeline by Nanotherapeutics Inc, H1 2017
    Botulism - Pipeline by Planet Biotechnology Inc, H1 2017
    Botulism - Pipeline by XOMA Corp, H1 2017
    Botulism - Dormant Projects, H1 2017
    Botulism - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Botulism, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    CytoDel LLC
    Hawaii Biotech Inc
    Medy-Tox Inc
    Microbiotix Inc
    Nanotherapeutics Inc
    Planet Biotechnology Inc
    XOMA Corp

    Request for Sample

    Report Url http://www.reportsweb.com//botulism-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//botulism-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//botulism-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments